Record second quarter Adjusted EBITDA1 of $508 million
Demonstrates strength and run rate potential of Parkland's diversified business
Advancing the Sunoco Transaction2
CALGARY, AB, Aug. 5, 2025...
Record second quarter Adjusted EBITDA1 of $508 million
Demonstrates strength and run rate potential of Parkland's diversified business
Advancing the Sunoco Transaction2
CALGARY, AB, Aug. 5, 2025...
Record second quarter Adjusted EBITDA1 of $508 million
Demonstrates strength and run rate potential of Parkland's diversified business
Advancing the Sunoco Transaction2
CALGARY, AB, Aug. 5, 2025...
TSX:GWO
Great-West Lifeco Inc.'s Quarterly Report to Shareholders for the second quarter of 2025, including its Management's Discussion and Analysis (MD&A) and consolidated financial statements...
CALGARY, Alberta, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Total Energy Services Inc. (“Total Energy” or the “Company”) (TSX:TOT) announces its consolidated financial results for the three months ended June 30, 2025.
Financial Highlights
Produced 3,863 vehicles in Q2Delivered 3,309 vehicles in Q2; up 38.2% compared to Q2 2024Q2 revenue of $259.4 millionQ2 GAAP diluted net loss...
LAS VEGAS, Aug. 5, 2025 /PRNewswire/ -- VIP Play, Inc. (OTCQB: VIPZ), VIP Play, Inc., a leader in immersive sports entertainment technology, and Decentral AI,...
MONTREAL, Aug. 5, 2025 /CNW/ - 5N Plus Inc. (TSX: VNP) ("5N+" or "the Company"), a leading global producer of specialty semiconductors and performance materials, today announced that it has entered into...
Wuppertal, Germany, August 5, 2025 - Aicuris Anti-infective Cures AG today announced initial clinical data from its ongoing first-in-human Phase 1 trial with AIC468. The novel antiviral antisense oligonucleotide is in development for the treatment of BK virus (BKV) infections in kidney transplant recipients. The interim results, presented at the World Transplant Congress in San Francisco on August 4, 2025, provide an overview of PK characteristics of AIC468 from the Phase 1 clinical trial in healthy volunteers.
Milan, Italy – August 5, 2025 – Tensive S.r.l, a clinical-stage advanced biomaterials medical device company, and the developer of REGENERA™ and SOFTAG™ bioresorbable scaffolds for breast reconstruction and tissue marking, has appointed Bill Hunter, MD, as Chairman of its Board of Directors. Dr. Hunter brings more than 30 years of leadership in the medical technology and life sciences sectors. His appointment reflects Tensive’s focus on strengthening its governance and expanding its global network as it accelerates toward pivotal clinical milestones and commercialization in the U.S. and Europe.
International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) today released its financial and operational results and related management’s discussion and analysis (MD&A) for the three and six months ended June 30, 2025. IPC also released its sixth annual Sustainability Report detailing IPC’s sustainability approach and initiatives.